What is Neomorph?
Neomorph operates at the cutting edge of the biotechnology sector, specializing in the science of targeted protein degradation and the development of molecular glues. By focusing on undruggable targets, the company aims to redefine the standard of care for complex human diseases. Its proprietary technology platform is designed to identify and modulate proteins that were previously considered inaccessible to traditional small-molecule drugs. This innovative approach positions Neomorph as a critical player in the next generation of drug discovery, leveraging a patient-first, science-driven methodology to translate complex biological insights into transformative clinical outcomes.
How much funding has Neomorph raised?
Neomorph has raised a total of $209M across 2 funding rounds:
Series A
$109M
Series B
$100M
Series A (2020): $109M with participation from Deerfield Communications Inc
Series B (2026): $100M led by Deerfield, Regeneron Ventures, Alexandria, and Longwood Fund
Key Investors in Neomorph
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the ecosystem with flexible funding models.
Regeneron Ventures
Regeneron Ventures is a firm dedicated to investing in innovative biotechnology and pharmaceutical companies to support the development of groundbreaking therapies and improve patient outcomes.
Alexandria
Alexandria Real Estate Equities is a REIT that provides specialized laboratory and office space for the life sciences industry, fostering innovation through strategic infrastructure support.
What's next for Neomorph?
With the recent influx of capital, Neomorph is poised to scale its internal pipeline and expand its collaborative research initiatives. The strategic focus will likely shift toward advancing lead candidates into human clinical trials, a critical phase for validating the efficacy of its protein degradation technology. Furthermore, the company is expected to leverage its strong investor network to enhance its operational capabilities and deepen its expertise in molecular glue discovery. As the firm matures, its ability to maintain a high-velocity research environment while navigating the complexities of clinical development will be the primary determinant of its long-term success in the global pharmaceutical market.
See full Neomorph company page
